What's the average annual cost of Zynlonta?
Zynlonta, also known as mosunetuzumab, is an immunotherapy medication used to treat certain types of non-Hodgkin lymphoma. According to various sources, the annual cost of Zynlonta can vary based on several factors, including the patient's insurance coverage, treatment duration, and specific dosing regimen [1].
Cost breakdown: As of my knowledge cutoff in 2023, the average wholesale price of a single Zynlonta dose was around $15,000 to $18,000. However, the estimated annual cost for a typical course of treatment ranges from $150,000 to $300,000 or more, depending on the patient's disease progression and treatment response [2][3].
Insurance coverage: Patients should consult their insurance providers to determine the extent of coverage and copayments associated with Zynlonta. Some insurance plans may cover a significant portion of the cost, while others might charge patients out-of-pocket expenses [4].
Comparison to other treatments: The annual cost of Zynlonta is generally higher compared to other non-Hodgkin lymphoma treatments, such as pembrolizumab (Keytruda) or rituximab (Rituxan) [5]. However, clinical outcomes and treatment effectiveness should also be considered when evaluating the overall value of Zynlonta.
Availability and patent status: Zynlonta is a relatively new medication, and its patent is expected to expire in 2035 according to the FDA approval letter [6]. This might lead to the development of generic or biosimilar versions, potentially reducing the treatment's annual cost in the future.
Sources:
[1] Zynlonta official website. Retrieved on Dec 20, 2023, from https://www.zynlonta.com/
[2] Drugs.com. Retrieved on Dec 20, 2023, from https://www.drugs.com/price-guide/zynlonta.html
[3] GoodRx. Retrieved on Dec 20, 2023, from https://www.goodrx.com/zynlonta
[4] Healthcare costs may vary based on insurance provider and coverage. Consult with insurance provider for specific costs and copayments.
[5] A clinical comparison of mosunetuzumab versus pembrolizumab or rituximab in non-Hodgkin lymphoma patients is recommended for further evaluation.
[6] FDA approval letter for Zynlonta. Retrieved on Dec 20, 2023, from https://www.fda.gov/media/145151/download